FP7H2020
Glaxosmithkline Biologicals SA
- Country
- BEBelgium
- Defence projects
- 0
- Projects, all programmes
- 23
- As coordinator
- 4
- EU contribution (CORDIS)
- EUR 15,138,399
- Active
- 2010 to 2021
Projects
23 projects, newest first
| Project | Programme | Year | Role | EU contribution |
|---|---|---|---|---|
| PROMISEPreparing for RSV Immunisation and Surveillance in Europe | H2020 | 2021 | Participant | EUR 0 |
| Inno4VacInnovations to accelerate vaccine development and manufacture | H2020 | 2021 | Participant | EUR 0 |
| VITALVaccines and Infectious Diseases in the Ageing PopuLation | H2020 | 2019 | Participant | EUR 0 |
| COMBACTE-CDICombatting Bacterial Resistance in Europe - Clostridium Difficile Infections | H2020 | 2017 | Participant | EUR 0 |
| DRIVEDevelopment of Robust and Innovative Vaccine Effectiveness | H2020 | 2017 | Participant | EUR 0 |
| RESCEUREspiratory Syncytial virus Consortium in EUrope - Sofia ref.: 116019 | H2020 | 2017 | Participant | EUR 0 |
| VAC2VACVaccine lot to Vaccine lot comparison by consistency testing. | H2020 | 2016 | Participant | EUR 0 |
| PERISCOPEPERtussIS COrrelates of Protection Europe - Sofia ref.: 115910 | H2020 | 2016 | Participant | EUR 0 |
| DiViNeSustainable downstream processing of vaccines through incorporation of nanobiotechnologies : novel affinity ligands and biomimetic membranes | H2020 | 2015 | Third party | Not stated |
| TBVAC2020TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development | H2020 | 2015 | Participant | EUR 0 |
| FLUCOPStandardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protection | FP7 | 2015 | Participant | Not stated |
| EXALTProposal to assess an innovative Immunotherapy, based on a thioredox peptide antigen, in a Phase I Trial for Type-1 Diabetes | FP7 | 2014 | Participant | EUR 285,403 |
| EbolaVacDevelopment of a Chimpanzee Adenovirus Type 3 Ebolavirus Zaire Vaccine | H2020 | 2014 | Coordinator | EUR 14,103,135 |
| ADJSYNUnderstanding how immunostimulant combinations in adjuvants synergise to enhance vaccine responses | FP7 | 2013 | Coordinator | EUR 169,800 |
| DAVIADThe development of a novel therapeutic vaccine for the selective treatment of the autoimmune disorder, Graves’ disease | FP7 | 2013 | Participant | EUR 14,761 |
| ADVANCEAccelerated Development of Vaccine benefit-risk Collaboration in Europe | FP7 | 2013 | Participant | Not stated |
| PEACHIPrevention of hepatitis C virus (HCV) and HIV-1 co-infections through induction of potent T cell responses using prime-boost viral vector vaccine regimens | FP7 | 2013 | Participant | Not stated |
| T-BACExploring the roles and plasticity of T-cell responses in anti-BACterial immunity | FP7 | 2013 | Coordinator | EUR 169,800 |
| MultiMalVaxA Multi-Stage Malaria Vaccine | FP7 | 2012 | Participant | EUR 25,000 |
| BIOVACSAFEBiomarkers For Enhanced Vaccine Safety | FP7 | 2012 | Participant | Not stated |
The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them (reuse under Commission Decision 2011/833/EU).
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.
Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.